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Abstract 
 
Purpose: Respiratory motion is a non-negligible source of uncertainty in radiotherapy. A common 
approach is to delineate the target volume in all respiratory phases (ITV) and to calculate a treatment 
plan using the average reconstruction of the four-dimensional computed tomography (4DCT) scans. In 
this study the extent of the interplay effect caused by interaction between dynamic dose delivery and 
respiratory tumor motion, as well as other motion effects were investigated. These effects are often 
ignored when the ITV concept is used. 
Methods and Materials: Nine previously treated patients with in ten abdominal or thoracic cancer 
lesions (3 liver, 3 adrenal glands and 4 lung lesions) were selected for this planning study. For all 
patients, phase-sorted respiration-correlated 4DCT scans were taken, and volumetric modulated arc 
therapy (VMAT) treatments were planned using the ITV concept. Margins from ITV to planning target 
volume (PTV) of 3-10 mm were used. Plans were optimized and dose distributions were calculated on 
the average reconstruction of the 4DCT. 4D dose distributions were calculated to evaluate motion 
effects, caused by the interference of dynamic treatment delivery with respiratory tumor motion and 
inhomogeneously planned target dose. These calculations were performed on the phase-sorted CT 
series with a respiration-correlated assignment of the treatment plan’s monitor units (MU) to the 
respiration phases of the 4DCT. The 4D dose was accumulated with rigid as well as deformable 
registrations of the CT series and compared to the original 3D dose distribution. Maximum, minimum 
and mean doses to ITV and PTV, and maximum or mean doses to organs at risk (OAR), were compared 
after rigid accumulation. The dose variation in the gross tumor volume (GTV) was compared after 
deformable registration. 
Results: Using rigid registrations, variations in the investigated dose parameters between 3D and 4D 
dose calculations were found to be within -2.1% to 1.4% for all target volumes and within -0.8% to 
1.7% in OAR. Using deformable registrations, dose differences in the GTV were below 3.8% for dose 
accumulation of lung and adrenal gland patients. For liver patients the used deformable registrations 
were not considered to be robust enough. It was also shown that a major part of the dose differences 
originates from the Hounsfield unit differences between 3D and 4D calculations, regardless of the 
interplay effect. 
Conclusion:  The evaluated motion effects during VMAT treatments resulted in negligible dose 
variability. Therefore, the approximation of calculating the dose on the average reconstruction of the 
4DCT (3D dose calculation), instead of calculating on the respiration-correlated phase CTs (4D dose 
calculation) with assignment of the corresponding MUs, gives acceptable results.  
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Zusammenfassung 
 
Hintergrund: Die Atembewegung ist eine nicht zu vernachlässigende Fehlerquelle in der 
Strahlentherapie. Ein gebräuchlicher Ansatz ist es, das Zielvolumen in allen Atemphasen zu konturieren 
(ITV) und den Bestrahlungsplan auf der gemittelten Rekonstruktion der vier-dimensionalen 
Computertomographie Aufnahme (4DCT) zu berechnen. Diese Studie untersucht den Interaktions-
Effekt (Interplay), welcher durch die Wechselwirkung zwischen der dynamischen Bestrahlung und der 
atembedingten Tumorbewegung zustande kommt, und andere Bewegungseffekte. Diese Effekte 
werden oft nicht berücksichtigt, wenn das ITV-Konzept verwendet wird. 
Methoden und Materialien: Neun vorgängig behandelte Patienten mit insgesamt zehn abdominalen 
oder thorakalen Tumorläsionen (3 Leber-, 3 Nebennieren- und 4 Lungentumoren) wurden für diese 
Planungsstudie ausgewählt. Für alle Patienten wurden phasensortierte, atemkorrelierte 4DCTs 
aufgenommen und Behandlungspläne für volumenmodulierte Bogenbestrahlung (VMAT) nach dem 
ITV-Konzept erstellt mit ITV-Expansionen von 3-10 mm zur Erstellung des Planungszielvolumens (PTV). 
Die Pläne wurden optimiert und die Dosisverteilungen auf der gemittelten Rekonstruktion des 4DCT 
berechnet. 4D-Dosisverteilungen wurden zur Auswertung der Bewegungseffekte berechnet, die durch 
die Interaktion der dynamischen Bestrahlung mit der respiratorischen Tumorbewegung und 
inhomogen geplanter Dosis im Zielvolumen verursacht sind. Dazu wurden Dosisberechnungen auf 
Phasen-sortierten CT Serien mit  atemkorrelierter Zuteilung der Monitoreinheiten (MU) des 
Behandlungsplanes zu den Atemphasen des 4DCT durchgeführt. Die 4D-Dosis wurde akkumuliert nach 
rigider sowie auch nach deformierbarer Registrierung der CT Serien und mit der originalen 3D-
Dosisverteilung verglichen. Die maximale, minimale und gemittelte Dosis im ITV und PTV und die 
maximale oder gemittelte Dosis in Risikoorganen (OAR) wurden im Falle rigider Registrierung 
verglichen und die Dosis zum Tumorvolumen (GTV) nach deformierbarer Registrierung. 
Resultate: Der Vergleich von 3D- und 4D-Berechnungen unter Verwendung rigider Registrierung ergab 
Differenzen in den untersuchten Dosisparameter von -2.1 bis 1.4% für alle Zielvolumina und von -0.8 
bis 1.7% für OARs. Bei den deformierbaren Registrierungen waren die Dosisdifferenzen im GTV für 
Lungen- und Nebennierenläsionen unter 3.8%. Im Falle der Leberläsionen erwies sich die 
deformierbare Registrierung als nicht robust genug. Es wurde ebenfalls gezeigt, dass ein grosser Anteil 
der gefundenen Dosisunterschiede durch die unterschiedlichen Hounsfield-Einheiten der 3D- und 4D-
Berechnungen herrühren, unabhängig vom Interaktions-Effekt.  
Zusammenfassung: Die Auswertung der Bewegungseffekte während VMAT-Behandlungen zeigte eine 
vernachlässigbare Dosisvariabilität. Daher liefert die Näherung, die Dosis auf der gemittelten 
Rekonstruktion des 4DCT (3D Dosisberechnung) zu berechnen, anstelle der Berechnung auf den 
atemkorrelierten Phasen-CTs mit entsprechender MU-Zuteilung, akzeptable Resultate. 
 
Schlüsselwörter: VMAT, Atembewegung, Interplay-Effekt, SBRT 
Introduction 
Respiration induced internal organ and tumor motion is a non-negligible source of uncertainty in 
radiotherapy and has been studied by several authors. Motion of thoracic and abdominal organs or 
tumors was found to be most prominent in superior-inferior (SI) direction. Motion amplitudes up to 
34 mm were found for liver tumors [1], 35 mm for lung tumors [2], and 27 mm for lesions in adrenal 
glands [3]. Respiratory motion affects the dose to the tumor in two ways: the gradient effect (motion 
blur) and the interplay effect [4]. Neglecting the tumor motion in treatment planning would lead to an 
underdosage at the edges of the moving target volume, the so called gradient or blurring effect. To 
prevent underdosage of the tumor, the internal target volume (ITV) concept is used as a common 
treatment approach [5]: A motion-encompassing delineation of the target volume defines the ITV and 
is constructed using respiration-correlated four-dimensional (4D) computed tomography (CT). The ITV 
concept ensures dose coverage of the tumor volume over the complete treatment session under free 
breathing, and prevents dose blurring at the tumor edges, as long as the dose is planned 
homogeneously. Since stereotactic body radiotherapy (SBRT) is often planned with inhomogeneous 
target dose the ITV concept is not fully capable to prevent dose blur. The tumor accumulates dose 
depending on its motion pattern through the high and low dose regions within the ITV. This is a pure 
spatial effect. If the beam itself moves or changes in size, temporal effects additionally alter the target 
dose. The interplay between beam alterations and tumor motion can lead to inhomogeneities in dose 
to the moving regions and partial target miss [4].  
Rietzel et al. [6] and Starkshall et al. [7] performed 4D treatment planning studies, investigating the 
impact of tumor motion on the dose distribution during intensity modulated radiotherapy (IMRT) 
treatments. They found dose perturbations of up to 2% and 5%, respectively, in the target volume but 
neglected temporal components in their calculations. For fixed-field IMRT the interplay effect between 
the multileaf collimator (MLC) and tumor motion was investigated by several authors [8], [9], [10]. 
Jiang et al. [9] found the interplay of fixed-field IMRT  to reach 18% dose difference for one fraction 
delivered with five fields, but to average out (1-2%) over 30 fractions. In stereotactic body radiotherapy 
(SBRT) the dose is delivered in only a few high-dose fractions and the dose averaging might be less 
pronounced than with conventional fractionation. Recent studies showed a negligible amount of 
interplay effect for lung SBRT during IMRT and VMAT treatments. Rao et al. [11] showed dose 
differences around 1% in the target. They included temporal effects, but without separating the 
contributions from different motion effects. Ong et al. [12] showed with film dosimetry that the motion 
effects on the delivered dose for RapidArc (Varian Medical Systems, USA) lung SBRT are not significant, 
if the irradiation is delivered in two or more arcs. Stambaugh et al. [13] used motion perturbation 
methods to reconstruct measured phantom dose received by a moving tumor. They were able to 
separate the interplay from the blurring effect and found nearly no impact of the interplay on the near-
minimum dose in the target. Zou et al. [14] showed less than 1.5% change in PTV dose coverage using 
4D dose calculations for lung SBRT using VMAT.  
With the ITV concept, which is often used in clinical practice, only the dose blurring at the tumor edges 
is accounted for, while the possible impact of the interplay effect and the inhomogeneously planned 
dose of SBRT treatments within the ITV are neglected in treatment planning. Therefore we conducted 
a 4DCT planning study to investigate the extent of different motion effects on the dose distribution 
caused by dynamic dose delivery of VMAT treatments and respiratory tumor motion for 
inhomogeneous SBRT treatment plans. Original treatment plans that were calculated and optimized 
on the averaged reconstruction of the 4DCT image set, were compared to 4D dose calculation based 
on the phase-sorted respiration-correlated 4DCT image sets using rigid and deformable dose 
accumulations. The methods used in this study allowed for a separate investigation of the temporal 
and spatial motion effects, and the dose variations caused by alternation in Hounsfield units (due to 
positional changes of the tumor during respiration) between the 3D and 4DCT. 
 
  
Materials and Methods 
 
Treatment planning 
Nine patients with a total of ten cancer lesions (3 liver, 3 adrenal glands and 4 lung lesions) were 
selected for this retrospective 4D-planning study. For all patients phase-sorted, 4DCT scans were 
obtained under free breathing with the SOMATOM Definition AS Open (Siemens AG, Germany) CT 
scanner, and the respiration patterns were recorded using the real-time position management system 
RPM (Varian Medical Systems,  USA). Using the recorded respiration pattern, 10 phase-sorted CT series 
(phase CTs) and the average of the 4DCT were reconstructed. The GTVs were segmented on all phase 
CTs. The ITV enclosing these GTVs was delineated on the average CT. Margins of 3 to 10 mm were 
added to the ITV in order to construct the PTV. Treatment plans were created for VMAT with 95% of 
the PTV receiving the prescribed dose, and a prescription isodose between 60% and 90%. This led to 
maximum inhomogeneities between 120% and 144%. The VMAT plans were  optimized and calculated 
on the average reconstruction of the 4DCT data set using the treatment planning system Eclipse 
(Varian Medical System, USA), with the analytical anisotropic algorithm (AAA 11.0.31) as a dose 
calculation model. This dose distribution was called the 3D dose distribution. Patient characteristics 
and treatment details such as dose prescription, number of arcs, modulation degree, size of ITV and 
PTV, ITV-to-PTV margins, the 3D extent of tumor motion and the respiratory period are summarized in 
Tab. 1. The modulation degree is a measure of the treatment plan’s complexity and modulation. We 
chose 𝑀𝑀𝑀𝑀 = ∑ (𝐴𝐴𝑇𝑇,𝑠𝑠 ∗ 𝑀𝑀𝑀𝑀𝑠𝑠)/∑ (𝐴𝐴𝑀𝑀𝑀𝑀𝑀𝑀,𝑠𝑠 ∗ 𝑀𝑀𝑀𝑀𝑠𝑠)𝑠𝑠𝑠𝑠  to report on modulation, where AT,s is the target area 
from a certain segment’s point of view, AMLC,s its MLC opening and MUs the monitor units delivered in 
this segment. This measure yields a value higher or equal to 1, where 1 is the case of no modulation. 
The tumor motion was determined in the 4DCT data set, by calculating the maximal 3D displacement 
of the center of gravity (COG) position for the GTV in the different respiration phases. The COG position 
was determined with an in house developed C++ program based on the Insight Toolkit and the 
Visualization Toolkit (Kitware Inc., USA). The respiratory periods were obtained by averaging the 
periods of the patient specific respiration curves, provided by the RPM measurement taken during the 
4DCT image acquisition.   
For the evaluation of different motion effects, four-dimensional dose calculations were performed 
with and without the temporal effects taken into account. 
 
4D dose calculation without interplay 
For the 4D dose calculation by taking tumor motion into account, but neglecting temporal effects, the 
monitor units (MU) of every arc segment had to be distributed uniformly to the ten breathing phases. 
The original plans were re-calculated on the ten different phase-correlated CT series, each with 10% 
of the MUs from the original plan applied. 
 
4D dose calculation with interplay 
For the investigation of the interplay effect, the MUs of the original plan had to be chronologically 
assigned to the dedicated respiration phases (Figure 1). Therefore a phase-specific sub-plan was 
generated for each respiratory phase. The arcs of the VMAT plan were segmented into control points 
(CP) with a determined gantry position, dose rate, and MLC shape. All CPs lying in the time sections of 
the same respiration phase contribute dose to this phase and were considered in a phase specific sub 
plan. For all other CPs, not contributing dose to that respiratory phase, the dose rate was manually set 
to zero in the corresponding sub plan. No changes were made to the other plan parameters. The ten 
phase specific VMAT plans were applied to the corresponding phases in the 4DCT data set, and the 
dose distributions were calculated. 
For the assignment of the control points to the respiratory phases, assumptions on the respiratory 
cycles were made. From the RPM measurements, the patients showed irregular respiratory patterns 
with mean periods from 2.6 to 5.7 s. For this study, steady respiratory cycles of 3.4 s were assumed for 
all patients. In our treatment system, 3.4 s is the delivery duration of 10 CP, leading to exactly 1 CP per 
respiratory phase. These assumptions facilitated the assignment process, in order to avoid dividing the 
MUs of one CP over multiple phases. 
 
Dose accumulation 
To calculate the composite doses from the dose distribution on the ten phase CT series, rigid and 
deformable dose accumulations were performed.  
Rigid dose accumulations were performed in Eclipse. Dose variations from 3D to 4D calculations in 
static structures such as PTV, ITV, and OARs that were delineated on the average reconstruction of the 
4DCT could be evaluated. Dose parameters as maximum, minimum, and mean dose were investigated 
for ITV and PTV, mean or maximum (spinal cord, ribs) for OARs.  The volume of the PTVs receiving 
100% of the prescribed dose (V100) was assessed from the dose-volume histograms. The 4D doses with 
rigid accumulations were also calculated with a slower respiratory period of 6.8 s with 2 CP per phase.  
In order to evaluate the dose variations to the moving GTV, 4D dose accumulations were performed 
with MIM Maestro (MIM Software Inc., USA). The built-in 4D dose accumulation tool of the software 
was used, which performs deformable registrations from all phase CTs against one chosen reference 
phase CT. Dose accumulations were performed against the end-of-exhale phase (50%) since it is the 
most stable, and against the 10% phase for comparison purposes. The accumulated 4D doses to the 
GTV delineated on the 10% and 50% phases were compared to the 3D doses to the GTV. The GTV dose 
values of the 3D calculations were estimated by averaging the minimum, maximum and mean dose 
values of the 10 drawn GTVs from the ten different respiration phases using the 3D dose distribution. 
 
Dependence on beam-on timing 
In the above mentioned 4D calculations, the assignment of the CPs to the phases, started with the 10% 
phase of the respiration cycle for all patients. To investigate the dependence of the interplay effect on 
the beam-on timing, meaning the concurrence of the switching-on of the beam with a specific 
respiration phase, the 4D dose distributions were calculated for  patient 9 (lung lesion), with 10 
different beam-on timings (starting at each of the 10 different respiration phases).  
 
Comparisons 
With and without the temporal splitting of the plans for the 4D dose calculation, and by using rigid and 
deformable registrations for dose accumulation, four distinct dose distributions can be calculated for 
every patient and compared against the original 3D distribution or against each other. Depending on 
the chosen dose calculations for comparison, four motion effects can be evaluated separately 
(summarized in Tab. 2):  
1) The dose difference caused by the alternation of Hounsfield units between the 3DCT (average 
reconstruction of the 4DCT) and 4DCT (phase CTs) 
2) The spatial dose accumulation effect due to inhomogeneous target dose 
3) The temporal interplay effect on the dose distribution of static volumes (PTV, ITV)  
4) The temporal interplay effect on the dose distribution of moving volumes (GTV).  
Comparing 4D dose distributions with temporal components to the distributions without temporal 
components, should therefore only deliver the dose variation in a moving target caused by the 
interplay effect. The Wilcoxon signed rank test was used to compare the calculations. A p-value of less 
than 0.05 was considered as significant.  
Spearman rank correlations with Bonferroni corrections for multiple testing were used to compare the 
modulation degree with the changes in PTV and ITV dose parameters.   
 
  
Results 
 
4D dose with rigid registrations 
Three 4D calculations were performed: one without interplay and two with interplay (with fast or slow 
respiratory period). The 4D dose was accumulated on the average reconstruction using rigid 
registrations and compared to the 3D dose (Figure 2). The relative dose differences from 3D to 4D 
calculations were small, within ±2.1%, but significant. 
The dose variations caused only by interplay effect, comparing 4D with against 4D without interplay, 
were significantly smaller than the variations from the 3D to 4D comparison. 
This indicates that the obtained dose variations between 3D and 4D calculations are mainly caused by 
the change of Hounsfield units between the 3DCT and 4DCT, and not by the interplay effect itself. No 
significant correlations between the dose differences and extent of tumor motion, modulation degree, 
or treatment site were found.  
 
4D dose with deformable registrations 
Due to the lack of visible structures in the liver that are required for deformable registrations, these 
patients were excluded from the analysis with deformable dose accumulation.  
In Figure 3, the results from the dose accumulation performed with deformable registrations are 
shown. The accumulations were performed twice, once with registering against and accumulating on 
the 10%-phase CT, and once against the 50%-phase CT as a reference CT. The comparison of 3D to 4D 
dose calculation showed dose variations of ±3.0%. Values up to 3.8% were found by comparing 4D 
dose calculations with and without interplay against each other, giving the pure temporal effects of 
the tumor motion.   
Different values between accumulations against 10% and 50% phases were observed, especially in the 
minimum dose to the GTV. Differences up to 2.8% were found, while the GTV maximum dose did not 
change much. 
 
Dependence on beam-on timing 
The dose differences for the ten calculations with different beam-on timings are shown in Figure 4a. 
4D calculations with fast respiratory cycle were investigated. A maximal dose spread over the ten 
calculations of 0.2% was found in the spinal cord. Comparing the 4D dose calculation with interplay 
effect against the 4D calculation without showed that all dose differences were in the range of ±0.1%. 
This is the amount of dose difference caused by temporal effects. 
The influence of beam-on timing on the dose variations to the moving GTV was also investigated for 
the 4D dose accumulations after deformable registrations against the 10%-phase CT. The dose 
differences of the 4D calculations, compared to 3D and 4D without interplay, are shown in Figure 4b. 
The differences in the mean dose to the GTV was well compensated by the 4D dose difference without 
regarding interplay, but the differences in the minimum and maximum dose ranged from -1.2% to 1.1% 
over the ten beam-on timings. 
 
Discussion 
 
VMAT treatment planning for lung, liver, and adrenal gland lesions is often performed on the average 
reconstruction of the 4DCT. However, this is an approximation of the dose delivered in the different 
breathing phases. The dose to a moving target depends on different motion effects. The dose 
difference caused by alternation in Hounsfield units between the 3DCT and 4DCT, the spatial dose 
accumulation effect due to inhomogeneous target dose, and the temporal interplay effect on the dose 
distribution of static volumes (PTV, ITV) or moving volumes (GTV).  
This study shows how 4D dose calculations can be performed to separately investigate these motion 
effects (Tab. 2). For the static ITV and PTV the overall dose variations caused by tumor motion were 
found to be small (±2%) and mainly caused by the alternation in Hounsfield units, while the temporal 
effect (interplay) showed minor impact on the dose distribution. Higher dose variations (up to 3.0%) 
were found in the moving GTV, calculated with deformable registrations for adrenal gland and lung 
patients, than for the static volumes under rigid dose accumulations. Especially higher contributions 
from temporal effects (up to 3.8%) were found.  
The small amount of dose difference found in this study is consistent with the results from the 4D 
planning studies performed by Rao et al. [11] and Zou et al. [14], as well as the phantom studies by 
Ong et al. [12] and Stambaugh et al. [13]. However it is in disagreement with the study published by 
Jiang et al. [9], which showed dose differences up to 18% to the target using a 5-field IMRT treatment 
technique. The high variation was measured near the tumor edge, where dose blurring is more 
pronounced. They did not use an ITV approach for blurring compensation, which explains the high dose 
difference. All investigated treatment plans included two or more arcs as proposed by Ong et al. Dose 
delivery with multiple arcs might act as a form of repainting the treatment volume in different 
respiratory phases, and thereby reducing dose inhomogeneities. 
Another way to reduce interplay might be the use of breath hold or gating methods, keeping the tumor 
in a ‘non-moving’ position whilst the treatment is delivered. But it has to be considered that those 
techniques require advanced technology and prolong the treatment time. 
Different dosimetric parameters (maximum, minimum, mean doses to predefined volumes) were 
evaluated in this work. These values are not bound to a spatial location within the examined volume. 
Therefore one could also be interested in γ-analyses of the dose distributions, but since the changes 
in minimum and maximum dose values are found to be small, this evaluation is assumed to show small 
variations as well. The evaluation of motion effects on the dose distribution was performed for the 
delivery of one single fraction only, and did not consider any fractionation, which could further reduce 
the dose differences caused by the interplay effect. The evaluation was also performed with only one 
specific beam-on timing. This could have an effect on the results, since the amount of interplay effect 
depends on the beam-on timing for the deformable dose accumulations as shown in Figure 4.  
The literature shows bigger discrepancies in the liver than in the lung using deformable image 
registration [15], [16] due to the lack of visible structures in the liver. Based on this, no deformable 
dose accumulations were performed for liver patients. The accumulations for the remaining patients 
were also found to result in different minimum and mean dose to the GTV for registrations against 
different reference phases (Fig. 3, right). The dose accumulations were performed against the 10% and 
50% phases, which correspond to the beginning and end of exhalation phases, respectively. These 
phases were chosen, because they showed less motion artifacts than the mid-respiration phases and 
therefore represent the GTV outline more accurately. However, by using these phases, the tumor is 
located at its most extreme positions and deformable dose accumulations might be more inaccurate 
than using a mid-ventilation position. The accuracy and robustness of the deformable registrations 
during the 4D dose accumulations performed with MIM Maestro cannot be verified and adapted, 
neither during nor after the registration process. Additionally, the GTVs of the different reference 
phases vary in location, size and shape, which include a delineation error as well. This might have an 
influence on the dose accumulation. More investigations are needed to separate the amount of dose 
difference originating from the spatial motion effects from the contribution due to possible 
inaccuracies in the deformable registrations.   
The differences between the accumulations against the different breathing phases showed dose 
variations to the same order of magnitude as the comparison of 3D and 4D calculated doses (Fig. 3), 
accumulated with deformable registrations. Therefore the inaccuracy of deformable registrations for 
dose accumulations is the limiting factor of this study and interferes with a robust separation of the 
dose differences according to the different motion effects. Nevertheless, the overall dose differences 
were found to be small and probably not clinically relevant. 
Another limitation of the study is the assumption of a constant respiratory period of 3.4 or 6.8 s, 
instead of using patient specific breathing cycles. This was done for easier handling of the assignment 
of CPs to the respiration phases.  However, the dose differences between 3.4s and 6.8s were small, 
and therefore a more adequate assignment of the MU to the phases would be expected to show dose 
differences in the same range.  
 
Conclusion 
 
In this work a planning study was performed to investigate the difference in the dose distribution 
between 3D planning on the average CT, and 4D planning for VMAT treatments of moving abdominal 
and thoracic cancer lesions, planned with inhomogeneous target dose. Two different approaches for 
dose accumulation, rigid and deformable registrations, were studied.  
Negligible dose variability was found. Therefore, the approximation of calculating the dose on the 
average reconstruction of the 4DCT (3D dose calculation), instead of on the respiration-correlated 
phase CTs with the assignment of the corresponding MUs, gives acceptable results. 
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Tables 
 
Table 1: Summary of patient characteristics: Tumor location, dose prescription, number of treated arcs, modulation 
degree, ITV and PTV size, ITV-to-PTV margin, motion amplitude and mean respiratory period. 
Patient Dose Prescription # Arcs 
Modulation 
Degree 
ITV 
Volume 
(cm3) 
PTV 
Volume 
(cm3) 
Margin 
(mm) 
Motion 
(mm) 
Respiratory 
Period 
(s) 
Liver         
1 5 x 8.5 Gy = 42.5 Gy 2 3.9 44.8 112.8 6 34 4.7 
2 4 x 12 Gy = 48 Gy 3 1.9 37.7 85.8 6 14 2.6 
3 10 x 5 Gy = 50 Gy 2 1.8 49.0 106.0 6 10 3.3 
Adrenal glands           
4 3 x 10 Gy = 30 Gy 2 1.6 29.7 49.1 3 9 4.1 
5 5 x 7 Gy = 35 Gy 3 2.9 36.1 153.9 10 21 5.7 
6 10 x 5 Gy = 50 Gy 2 1.4 28.4 66.2 5 7 3.0 
Lung           
7 5 x 9 Gy = 45 Gy 3 2.5 13.0 38.9 6 10 4.8 
8 5 x 6.5 Gy = 32.5 Gy 2 1.9 73.6 148.2 6 8 4.8 
9 8 x 7.5 Gy = 60 Gy 4 1.4 94.6 161.1 5 6 3.0 
10 3 x 12.5 Gy = 37.5 Gy 4 2.1 9.2 25.5 5 9 3.7 
 
 
 
Table 2: Choice of the two compared calculation methods determines the investigated motion effect. 
The dose difference between two dose calculations (3D or 4D, with or without interplay, rigid or 
deformable registrations) can be caused by: Density (Hounsfield unit) differences (HU) between the 
3D and 4DCTs, the spatial effect (Spatial) on dose accumulation caused by inhomogeneously planned 
ITV dose and the temporal effects (Temporal) due to interplay for static or moving (dynamic) volumes. 
Without Interplay 
4D rigid HU  
With Interplay 
4D rigid 
HU  
Temporal (static) Temporal (static) 
Without Interplay 
4D deformable 
HU 
Spatial Spatial 
With Interplay 
4D deformable 
HU 
Spatial 
Temporal (dynamic) 
Spatial 
Temporal (dynamic) Temporal (dynamic) 
 3D original Without Interplay 4D rigid 
Without Interplay 
4D deformable 
  
Figures 
 
 
Fig. 1: Assignment of control points: The respiration curve is divided into 10 equally long phases. The 
different control points (squares in the CP sequence) were assigned to the respiration phases. A: Beam-
on timing coincides with 10% phase. B: Beam-on with 30% phase. A1, A2, A3: CP sequence of a 
particular sub plan only delivering dose to the corresponding respiration phase. 
 
 
Fig. 2: After rigid registrations: Boxplots of relative dose variations of the 10 lesions for dose 
parameters (minimum, maximum or mean dose) of ITV, PTV and OARs. Box edges cover the 25% and 
75% quantiles and whiskers exceed up to maximal 1.5 times the box width on both sides. Outliers are 
marked with circles. Comparisons of original 3D dose calculations to 4D calculations with interplay 
under fast respiration (black), to 4D with interplay under slow respiration (dark gray) and to 4D without 
interplay (gray) and between the 4D calculations with and without interplay (light gray) are shown, 
with rigid registrations used for dose accumulation.  Contra = contralateral, ipsi= ipsilateral. Numbers 
give the number of patient with this OAR. 
  
Fig. 3: After deformable registrations: Boxplots of relative dose variations of the 7 lesions dose 
parameters (minimum, maximum and mean dose) of the GTV. Comparisons of original 3D dose 
calculations to 4D calculations with interplay (black) and to 4D without interplay (gray) and between 
the 4D calculations with and without interplay (light gray) are shown, with deformable registrations 
against the 10% (top) and the 50% phase (middle) for dose accumulation. Differences between the 
two dose accumulations on the 10% and 50% phases are shown (bottom).  
 
Fig. 4: Influence of beam-on timing for one patient with a lung lesion: Top: Dose differences between 
4D dose calculations with interplay compared to 3D dose calculations considering 10 different beam-
on timings. Bottom: Dose differences between 4D dose calculations with and without interplay using 
a) rigid or b) deformable registrations for dose accumulation. 
 
